Immunotherapy + Neoadjuvant Chemoradiation may Improve Outcomes in Esophageal Cancer

Abstract

In patients diagnosed with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made tumors more amenable to surgery, which was associated with significantly improved outcomes, including a better survival rate rather compared to non-surgical treatment alone.